BioAge Labs, Inc (BIOA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
BioAge Labs, Inc stock (BIOA) is currently trading at $16.11. BioAge Labs, Inc PE ratio is 1.42. BioAge Labs, Inc PS ratio (Price-to-Sales) is 136.19. Analyst consensus price target for BIOA is $49.25. WallStSmart rates BIOA as Sell.
- BIOA PE ratio analysis and historical PE chart
- BIOA PS ratio (Price-to-Sales) history and trend
- BIOA intrinsic value — DCF, Graham Number, EPV models
- BIOA stock price prediction 2025 2026 2027 2028 2029 2030
- BIOA fair value vs current price
- BIOA insider transactions and insider buying
- Is BIOA undervalued or overvalued?
- BioAge Labs, Inc financial analysis — revenue, earnings, cash flow
- BIOA Piotroski F-Score and Altman Z-Score
- BIOA analyst price target and Smart Rating
BioAge Labs, Inc
📊 No data available
Try selecting a different time range
BIOA Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · BioAge Labs, Inc (BIOA)
BIOA trades at a significant discount to its Graham intrinsic value of $92.55, offering a 78% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
BioAge Labs, Inc (BIOA) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
BioAge Labs, Inc (BIOA) Key Strengths (1)
65.01% held by institutions, strong professional interest
Supporting Valuation Data
BioAge Labs, Inc (BIOA) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 136.2x annual revenue
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Supporting Valuation Data
BioAge Labs, Inc (BIOA) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 8.0/10) while 5 fall into concern territory (avg 2.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (136.19), Price/Book (2.90) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -25.60%, Operating Margin at -1127.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -25.60% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BIOA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BIOA's Price-to-Sales ratio of 136.19x sits near its historical average of 145.69x (14th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 14% below its historical high of 157.5x set in Feb 2026, and 3% above its historical low of 132.09x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~157.5x as trailing revenue scaled faster than the stock price.
Compare BIOA with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for BioAge Labs, Inc (BIOA) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
BioAge Labs, Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Debt-to-equity ratio of 0.03 indicates a conservative balance sheet with 216M in cash.
Spending 313% of revenue (19M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -16M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact BioAge Labs, Inc.
Bottom Line
BioAge Labs, Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:09:47 AM
About BioAge Labs, Inc(BIOA)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
BioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to various customers in the chemical market primarily in the United States and Canada. The company is headquartered in Montreal, Canada.